Standard usage and dosage specifications of Febuxostat/Febuxostat

Febuxostat is an oral xanthine oxidase inhibitor widely used to treat adult patients with chronic hyperuricemia and gout symptoms. The standard usage and dosage are designed to achieve long-term control of blood uric acid while ensuring medication safety. Typically, the starting dose for adult patients is 40 mg once daily. After monitoring serum uric acid levels for two weeks, if the target level (less than 6 mg/dL) is not reached, the dose may be adjusted to 80 mg once daily. For patients with mild or moderate renal impairment, no dose adjustment is required, while in patients with severe renal impairment, the upper daily dose should be controlled at 40 mg to reduce the risk of potential adverse reactions.

In terms of taking method, febuxostat can be taken orally with meals or on an empty stomach. It is not affected by antacids and is convenient for long-term home maintenance treatment. It is recommended to regularly monitor blood uric acid, liver function and clinical symptoms during medication to evaluate efficacy and safety. For patients taking combined medications, attention should be paid to the possibility of drug interactions between febuxostat and xanthine oxidase substrate drugs (such as azathioprine, mercaptopurine), resulting in elevated plasma concentrations and increased risk of toxicity. Doses should be adjusted or plasma concentrations monitored under the guidance of a physician.

Reasonable implementation of standard usage and dosage not only helps stabilize blood uric acid, but also effectively reduces complications such as acute attacks of gout and uric acid stones. The efficacy of febuxostat may be further enhanced when combined with lifestyle interventions, such as limiting high-purine foods, increasing water intake, and maintaining a healthy weight.

In short, following standardized dosage and usage, combined with individualized monitoring and comprehensive management, is the key to achieving safe, effective, and long-term management of febuxostat in the treatment of chronic hyperuricemia.

Reference materials:https://www.drugs.com